Indacaterol/glycopyrronium is cost-effective compared to salmeterol/fluticasone in COPD: FLAME-based modelling in a Swedish population
Crossref DOI link: https://doi.org/10.1186/s12931-017-0688-5
Published Online: 2017-12-11
Published Print: 2017-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Bjermer, Leif
van Boven, Job F. M.
Costa-Scharplatz, Madlaina
Keininger, Dorothy L.
Gutzwiller, Florian S.
Lisspers, Karin
Mahon, Ronan
Olsson, Petter
Roche, Nicolas
Funding for this research was provided by:
Novartis Pharma AG (Switzerland)